

SUSTAINING THE MOMENTS* WITH CONFIDENCE¥1

*Lucrin Depot achieved durable suppression of testosterone below castrate levels (<50 ng/dL) for all doses in >93% of patients by Week 4 which was maintained for the duration of the study period.[1]
¥Lucrin has a well-established safety profile[1]

- **FLEXIBLE#** #1-, 3-, 4- & 6- monthly dosing options[1]
- CONVENIENT PRE-FILLED DUAL CHAMBER SYRINGE[1]
- NO REFRIGERATION OR TIME TO WARM REQUIRED[1]
- SMALL NEEDLE GAUGE[2†] †Needle gauge is 23CH on all Lucrin doses

PBS Information: Restricted benefit. Treatment of locally advanced (stage C) or metastatic (stage D) carcinoma of the prostate.

Please review full Product Information (PI) before prescribing LUCRIN® Depot PDS. Full PI is available on request from AbbVie Pty Ltd by calling 1800 043 460, or at www.medicines.org.au.

MINIMUM PRODUCT INFORMATION Lucrin Depot PDS is a Prescription Medicine containing leuprorelin acetate 7.5 mg, 22.5 mg, 30 mg or 45 mg for injection. INDICATION: Palliative treatment of metastatic or locally advanced prostate cancer. **CONTRAINDICATIONS:** Gonadotropin-releasing hormone (GnRH), GnRH agonists, nonapeptide and excipient hypersensitivity; pregnancy; lactation. **PRECAUTIONS:** Tumour flare (presented as transient worsening of symptoms and/or occurrence of additional signs/symptoms of prostate cancer may develop during the first few weeks of treatment, e.g. bone pain; ureteral obstruction and spinal cord compression which may contribute to paralysis [with or without fatal complications]). Patients with metastatic vertebral lesions and/or with urinary tract obstructions should be closely observed during the first few weeks of therapy. Bone mineral density changes; convulsions; depression; hyperglycaemia; increased risk of developing diabetes; QT prolongation; increased risk of developing myocardial infarction, sudden cardiac death and stroke have been reported in men receiving GnRH agonists. In patients treated with GnRH analogues for prostate cancer, treatment is usually continued upon development of castrate-resistance. Reference should be made to relevant guidelines. Serum testosterone levels should be checked periodically to assure appropriate suppression. In addition, PSA levels should be monitored to identify potential disease progression. **ADVERSE EFFECTS:** 'Flare' phenomenon; asthenia; general pain; headache; injection site reaction; GI disorders; oedema; hot flushes and sweats (physiological effect of decreased testosterone); joint disorders; skin reaction; urinary disorders. Reported for Depot 1-month only: peripheral oedema. Reported for Depot 3-month only: arthralgia; constipation; testicular atrophy (physiological effect of decreased testosterone). Reported for Depot 4-month only: Flu syndrome Reported for Depot 6 Month only: injection site pain; fatigue (physiological effect of decreased testosterone). See full PI for details. **INTERACTIONS WITH OTHER MEDICINES:** No pharmacokinetic-based drug-drug interaction studies have been conducted with Lucrin. However, because leuprorelin acetate is a peptide that is primarily degraded by peptidase and the drug is only about 46% bound to plasma proteins, drug interactions would not be expected to occur. Since androgen deprivation treatment may prolong the QT interval, concomitant use with medicinal products known to prolong the QT interval or able to induce Torsade de pointes such as class IA (e.g. quinidine, disopyramide, procainamide) or class III (e.g. amiodarone, sotalol, dofetilide, ibutilide) antiarrhythmic medicinal products, methadone, moxifloxicin, antipsychotics, etc. should be carefully evaluated. **DOSAGE AND ADMINISTRATION:** Intramuscular injection. Vary site of administration. 1-month 7.5 mg PDS: one injection every 4 weeks. 3-month 22.5 mg PDS: one injection every 12 weeks. 4-month 30 mg PDS: one injection every 16 weeks. 6-month 45 mg PDS: one injection every 24 weeks. Version 13. **References: 1.** LUCRIN® Product Information. **2.** Abbvie Data on File. CLA-AU-200018. LUCRIN®, LUCRIN Depot® and AbbVie® are registered trademarks of AbbVie Inc. AbbVie Pty Ltd, Mascot NSW 2020. Ph: 1800 043 460. ABN 48 156 384 262. AU-LUCR-210101. August 2021.

abbvie

LUCRIN®
LEUPRORELIN ACETATE